In a Phase 2 trial, Dactolisib (RTB101), a TORC1 inhibitor, was well tolerated and reduced the incidence of respiratory tract infections in adults age 65 and older, particularly those with asthma, according to research presented at ATS 2019.
When administered once daily for 16 weeks during winter cold and flu season, Dactolisib 10 mg was safe and well tolerated and reduced the percentage of subjects with laboratory-confirmed RTIs by 30.6% compared to placebo.
In adults age ?85 years or age ?65 with asthma there was a 66.7% and 68.9% reduction reduction in the incidence of respiratory tract infections, which cause the majority of asthma exacerbations.
Subjects with asthma also experienced a 78.6% reduction in the adjusted rate of laboratory-confirmed RTIs.
Efficacy of dactolisib was additionally supported by an analysis of all RTIs in asthmatics that revealed a 58.2% reduction in the percentage of subjects with RTIs and 66.5% reduction in the adjusted rate of RTIs compared to placebo.